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Abstract
Aldosterone plays an important role in the regulation of blood pressure, body 
fluid, and electrolyte homeostasis. Overactivation of aldosterone/ mineralocorticoid 
receptor (MR) pathway leads to hypertension, atherosclerosis, vascular  damage, 
heart failure, and chronic kidney disease and is involved in many other diseases 
 associated with endothelial dysfunction, inflammation, fibrosis, and metabolic 
 disorders. Aldosterone is a final product of the renin-angiotensin-aldosterone 
system (RAAS), and its production is activated by angiotensin II, while 
 angiotensin-(1–7) negatively regulates angiotensin II-mediated aldosterone 
 production and in some experimental models inhibits aldosterone-induced damage 
in target tissues. In fact, the aldosterone/mineralocorticoid receptor-dependent 
pathway is regulated upstream by at least two major axes of RAAS: classical axis 
(ACE/Ang II) and nonclassical axis (ACE2/Ang-(1–7)). The relative balance 
between these two axes determines aldosterone production and activity. To better 
understand the  regulation of aldosterone activity in physiology and diseases, it is 
important to analyze the role of aldosterone/mineralocorticoid receptor-dependent 
pathways in the context of upstream angiotensin pathways as some of the recently 
described mechanisms of RAAS represent possible novel upstream targets to inhibit 
aldosterone/mineralocorticoid receptor-dependent responses. In this review, we 
highlight the complexity of angiotensin pathways focusing on their role in various 
tissues in heart failure, with particular emphasis on nonclassical pathways including 
protective ACE2/Ang-(1–7) axis and detrimental Ang-(1–12)/chymase/Ang II axis.
Keywords: angiotensin pathways, angiotensin-converting enzyme (ACE), 
angiotensin-converting enzyme 2 (ACE2), chymase, aldosterone, heart failure
1. Introduction
The renin-angiotensin-aldosterone system (RAAS) includes angiotensin (poly)
peptides such as angiotensinogen, angiotensin I, angiotensin II, angiotensin III, 
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angiotensin IV, angiotensin-(1–9), angiotensin-(1–7), alamandine and angiotensin A 
[1], and a number of enzymes regulating the production of particular angiotensins 
(renin, angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 
2 (ACE2), chymase, neutral endopeptidase (NEP), prolyl endopeptidase (PEP), 
and others) [2–5], as well as specific receptors such as AT1R, AT2R, AT4R, MasR, or 
MrgDR, activated in response to a given angiotensin sub-type [5]. All these elements 
contribute to the incredible complexity of the RAAS that is not perceived any more 
like a simple linear system with two major enzymes (renin and ACE) generating 
Ang II but rather as a network of tightly regulated peptides and enzymes endowed 
not only with endocrine (tissue to tissue) but also paracrine (cell-to-cell) and an 
intracrine (intercellular/nuclear) activities. There is also abundant evidence for the 
importance of tissue-based angiotensin pathways that seems to be heterogeneously 
organized in various organs which act independently of the RAAS in plasma. The 
major role of the protective ACE2/Ang-(1–7) axis counteracting classic ACE/Ang II  
axis has also been well documented. A simplified scheme of the angiotensin  pathways 
with major angiotensins, enzymes, and receptors is shown in Figure 1.
The final RAAS product, aldosterone, plays an important role in the regulation 
of blood pressure, body fluid, and electrolyte homeostasis, but overactivation 
of aldosterone/mineralocorticoid receptor (MR) pathway leads to  hypertension, 
atherosclerosis, vascular damage, heart failure, and chronic kidney disease and 
is involved in many other diseases associated with endothelial  dysfunction, 
 inflammation, fibrosis, metabolic disorders, and organ damage [6–9]. The 
 overstimulation of AT1R (by Ang II and its metabolites) and increased aldosterone 
production result among others in increased ROS production and NADPH oxidase 
activation [9, 10] that contribute to cardiac and vascular pathology [11].
The importance of RAAS in cardiovascular, hypertensive, and kidney 
 diseases has been firmly established by therapeutic effects of renin inhibitors, 
Figure 1. 
Simplified scheme of major angiotensin pathways with respective enzymes and receptors. Abbreviations: 
Ang, angiotensin; ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; NEP, 
neutral endopeptidase; AT1R, angiotensin receptor type 1; AT2R, angiotensin receptor type 2; AT4R, 
angiotensin receptor type 4; MasR, Mas receptor; MrgD, MAS-related G protein-coupled receptor member 
D. Colors: Red, classical axis (renin/ACE/Ang II); green, nonclassical protective axis (ACE2/Ang-(1–7); 
orange, non-renin non-ACE, chymase-dependent axis Ang-(1–12)/chymase/Ang II axis; gray, other 
elements.
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angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers 
(ARBs), and finally mineralocorticoid receptor antagonists (MRA). Importantly, 
these drugs influence not only the downstream but also the upstream activity of the 
RAAS. This phenomenon is rather overlooked but needs to be taken into account 
in designing the optimal RAAS-targeted therapy for the treatment of a variety of 
diseases. In particular, evidence accumulated showing reciprocal regulation of 
major angiotensins and aldosterone/mineralocorticoid pathway (Figure 2).
Indeed, MRA modify upstream pathways. MRA decrease ACE activity and increase 
ACE2 activity, suggesting a protective role for MRA is not only mediated by the direct 
inhibition of MR-dependent pathways but also by increasing the expression of ACE2 
and generating angiotensin-(1–7) and decreasing the formation of angiotensin II as 
documented in heart failure (HF) patients and in the rat model of renal  dysfunction 
[12–14]. Noteworthy, plasma levels of Ang-(1–7) increase after treatment with 
ACE-I or ARB [15–20]. On the other hand, aldosterone upregulates the expression 
and  activity of upstream ACE [21]. Furthermore, aldosterone-induced accelerated 
production of an angiotensin II is negatively regulated by angiotensin-(1–7) via the 
Mas receptor and JAK/STAT signaling in human adrenal cells [22]. Angiotensin-(1–7) 
may also suppress aldosterone-induced damage in target tissues. For example, 
 angiotensin-(1–7) inhibits hypertensive kidney damage induced by  infusion of 
 aldosterone [23]. Interestingly, this effect is independent of blood pressure and  mediated 
by the suppression of the expression of TGF, FGF, TIMP, and ROS production  
suggesting that the inhibition of aldosterone activity by angiotensin-(1–7) occurs 
locally in the kidney [23]. Angiotensin-(1–7) may inhibit angiotensin II-mediated 
effects on aldosterone not only by counterbalancing effects mediated by the activation 
of Mas receptor [23] but also by acting as natural-biased ligand for the AT1 receptor, 
behaving as a natural competitive neutral antagonist for AT1 in G protein-dependent 
signaling while  simultaneously acting as an agonist for β-arrestin-related signaling [24].
In summary, aldosterone/mineralocorticoid receptor-dependent  signaling 
pathways are under upstream regulation by at least two major axes of the RAAS: 
classical axis (ACE/Ang II) and nonclassical axis (ACE2/Ang-(1–7)). The  relative 
ratio of these two axes determines aldosterone production and activity, and 
 reciprocally aldosterone production might affect upstream mechanisms of RAAS. 
For the better understanding of the regulation of aldosterone/mineralocorticoid 
 receptor-dependent pathways and optimal pharmacotherapy of diseases  associated 
with aldosterone overactivation, one needs to take into account the regulatory 
Figure 2. 
Scheme showing the reciprocal regulation of major angiotensins and aldosterone/mineralocorticoid pathway. 
Abbreviations: PEP, prolyl endopeptidase (see Figure 1 for other abbreviations and colors coding).
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role of at least two major angiotensin pathways, the balance of which determines 
aldosterone/mineralocorticoid receptor-dependent pathways. Here, we review the 
complexity of local angiotensin pathways focusing on their role in various tissues in 
heart failure with particular emphasis on nonclassical pathways including protective 
ACE2/Ang-(1–7) axis and detrimental Ang-(1–12)/chymase/Ang II axis.
2.  Classical (ACE/Ang II/AT1R) and nonclassical (ACE2/Ang-(1–7)/
MasR) axes of RAAS
The classical RAAS pathway involves renin secreted by the kidney to produce 
Ang I from angiotensinogen (derived from the liver) (Figures 1 and 2). Ang I is 
then converted mainly through ACE to Ang II which predominantly stimulates 
the AT1 receptor, the major culprit receptor for Ang II-induced cardiovascular 
pathology. Indeed, overactivation of AT1R contributes to the pathophysiology of 
heart failure inducing cardiac fibrosis, inflammation, cell proliferation, coronary 
vasoconstriction, and cardiomyocyte hypertrophy, as well as apoptosis [25], 
cardiac remodeling [25, 26], vascular stiffness and atherosclerosis [27], endothelial 
 dysfunction, oxidative stress, or insulin resistance [28]. Ang II may also stimulate 
AT2R that has a vasoprotective profile—anti-inflammatory, antifibrotic, and 
anti-apoptotic—involving the activation of bradykinin/NO/cGMP system [29]. 
AT2R is linked also to the regulation of vascular and cardiac growth responses [30]. 
Activation of AT2R after cardiac injury decreases sympathetic overstimulation and 
stimulates cardiac regeneration with increasing coronary vasodilation [31]. It was 
also shown that AT2R stimulation may indirectly increase ACE2 activity, Ang-(1–7), 
and MasR expression level [32]. Additionally, in physiological conditions, AT2R 
may downregulate [33] or directly inhibit AT1R [34–36]; however, physiological AT2R 
activation occurs mostly at embryonal stage (responsible for fetus  development), 
while in adulthood AT2R expression is low [36, 37]. Nevertheless, it may still be 
detectable in different organs, including the heart in particular in pathological 
 conditions. Both AT1R and AT2R are located on cell surfaces or nuclear membranes 
[38–40].
The second dominant RAAS pathway opposing the classical axis (ACE/Ang II/
AT1R) is the ACE2-dependent pathway, leading to the generation of Ang-(1–7) 
acting on Mas receptors. The major player in this system, ACE2, converts Ang I 
to Ang-(1–9), Ang II to Ang-(1–7), and Ang A to alamandine [41]. Ang-(1–7) is 
the main opposing signaling peptide to Ang II with a broad range of effects in 
 different organs. The most significant activity of Ang-(1–7) includes  vasodilation 
and anti-proliferative and anti-inflammatory effects that are mediated by Mas 
 receptors [42]. Alamandine (the product of Ang A and Ang-(1–7)), despite 
its  similarity in function to Ang-(1–7), acts on different receptors identified 
as Mas-related G protein-coupled receptor member D (MrgDR) [43]. Both of 
these vasoprotective angiotensins induce endothelial-dependent vasorelaxation 
and central nervous system-dependent cardiovascular effects [41], but their 
 activity is not always identical [44, 45]. Importantly, the Mas receptor was found 
in  cardiomyocytes and cardiac endothelial cells [46–48], as well as on cardiac 
 fibroblasts [49]. MasR genetic deletion leads to impairment of cardiac function and 
endothelial dysfunction pointing to the important protective role of this  receptor 
in cardiac and vascular physiology. Although there is equivocal evidence that 
Ang-(1–7) has vasoprotective, cardioprotective, and anti-inflammatory effects, 
still it is not clear if all of the effects of ACE2 pathway are mediated by Ang-(1–7) 
and by MasR. Ang-(1–7), alamandine, and bradykinin could act in concert as 
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their concentrations increase simultaneously with decreased ACE/ACE2 ratio and 
Ang-(1–7)-mediated effects in some systems are inhibited by B2 receptor antagonists 
[50]. Although evidence supporting the protective role of ACE2/Ang-(1–7) axis is 
convincing, it is still not clear if ACE2 is the only enzyme that plays a key role in 
Ang-(1–7) generation in various pathologies.
The major difference between ACE and ACE2 (which are quite similar in 
structure: 42% of amino acids are identical in the extracellular domain) is that ACE 
acts as dipeptidyl carboxypeptidase (removing a dipeptide from the C-terminus of 
substrate), while ACE2 acts as a mono-carboxypeptidase (removing a single amino 
acid) [2, 3]. Both enzymes are type I transmembrane proteins with an extracellular 
N-terminal domain containing the catalytic site and an intracellular C-terminal 
tail. ACE inhibitors do not act on ACE2 catalytic activity, the latter is affected by 
MLN 4760, a prototypic ACE2 inhibitor [51]. In the healthy heart, ACE2 is present 
in cardiomyocytes, fibroblasts, and coronary endothelial cells [52], while ACE is 
mainly found in endothelial cells [53]. ACE2 catalytic efficiency is 400-fold higher 
with Ang II as a substrate than with Ang I, suggesting a dominant role for ACE2 in 
Ang II metabolism as compared with Ang I metabolism. In this way, ACE2 coun-
terbalances ACE activity mainly at the level of Ang II. In fact, ACE increases Ang II 
levels, and ACE2 decreases Ang II levels resulting in the activation of MasR instead 
of AT1R. The relative significance of ACE2 converting Ang I to Ang-(1–9) and Ang 
A to alamandine seems to be of less importance, but further studies are needed.
The discovery of ACE2 in 2000 [3] and subsequent studies documenting 
 opposite actions of ACE2/Ang-(1–7)/MasR axis as compared to ACE/Ang II/AT1R 
axis have revealed this pathway as a major protective arm of RAAS.
3. Other angiotensin pathways, enzymes, and receptors
In addition to ACE/Ang II/AT1 and ACE2/Ang-(1–7)/MasR axes, the couple 
of other angiotensin axes has been proposed as important counterparts of RAAS 
including the protective axes of Ang III/aminopeptidase N(APN)/Ang IV/insulin-
regulated aminopeptidase (IRAP)/AT4R and Ang II/aminopeptidase A(APA)/Ang 
III/AT2R/NO/cGMP [54] (Figure 1). Additionally, the prorenin/renin/prorenin 
receptor was proposed to constitute an important vasopressor pathway in addition 
to the ACE/Ang II/AT1 axis, with an emerging role for the prorenin receptor (PRR) 
[55] that may affect intracellular signaling pathways in an angiotensin-independent 
manner [56, 57]. On the other hand, the generation of Ang III stimulating 
directly AT2R and AT4R after conversion of Ang III to Ang IV represents a novel 
 vasoprotective arm of angiotensin pathways regulating RAAS with vasodilator 
properties, as well as promoting endothelial cell proliferation [58, 59].
Additionally, intracellular Ang II in various tissues may be generated in a non-
ACE-dependent way from Ang-(1–12) via chymase, particularly in pathological 
conditions [59, 60] (Figure 1). The detrimental effects of Ang-(1–12)/chymase/
Ang II axis seem to play an important role, for example, in heart failure [61]. 
Ang-(1–12) when activated may lead to tissue remodeling and potentiated vascular 
as well as cardiac contractility [62, 63]. The independence of intracellular Ang 
II production from extracellular system was confirmed by studies showing that 
chronic administration of losartan and lisinopril did not influence cardiac Ang II 
content, despite antihypertensive effects of these treatments linked to circulating 
angiotensins [59].
Many other enzymes are also implicated in the generation of Ang II (besides 
ACE and chymase), including chymostatin-sensitive Ang II-generating enzyme 
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(CAGE), endopeptidase-2, meprin [64], cathepsins D and G, or tonin [65–67]. 
Various types of aminopeptidases (-A,-N,-M,-B) were suggested to take part in 
the generation of Ang III or Ang IV. Production of Ang-(1–9) may be mediated 
by  carboxypeptidase A (CP-A) or cathepsin, while the generation of Ang-(1–7) 
can occur by activation of prolyl endopeptidase (PEP), neutral endopeptidase 
[68], neprilysin (NEP) [69–71], or thimet oligopeptidase (TOP) [72]. Prolyl 
 endopeptidase has also an influence on tissue angiotensins which makes it an 
interesting target for pharmacotherapy [73].
The physiological and pathophysiological relevance of these multiple enzymes 
in the regulation of the angiotensin pathways influencing the RAAS network as 
well as the pathophysiological importance of prorenin/renin/prorenin receptor 
pathways (Figure 1) still needs to be delineated. Currently, among nonclassical 
pathways influencing angiotensin pathways, protective ACE2/Ang-(1–7)/MasR axis 
and detrimental Ang-(1–12)/chymase/Ang II axis are best characterized and seem 
to play a major role in heart failure. Both of them could influence the activity of 
aldosterone/mineralocorticoid receptor-dependent pathways (Figure 2).
4. Alterations of RAAS in heart failure
It is well known that overactivation of RAAS plays a crucial role in heart failure 
progression, while the inhibition of RAAS (by ACE-I, ARB, and MRA) represents 
a cornerstone for the current pharmacotherapy of HF [74]. It is clear that systemic 
RAAS and local angiotensin pathways in tissues act independently as alterations 
in systemic and tissue-derived angiotensins in HF progression do not coincide. 
Moreover, the range of concentrations of angiotensins in plasma and tissue differs, 
that is, cardiac Ang II concentration is about 100-fold higher than that of plasma 
[75]. This phenomenon may result from intrinsic cardiac Ang I production, which 
was estimated to represent about 90% of cardiac Ang I and about 75% cardiac Ang 
II [76], the rest being regulated by RAAS components taken to the tissue from the 
systemic circulation, for example, by plasma-derived renin [77]. Cardiac intrinsic 
angiotensin pathway activity gains particular importance in course of heart 
failure, activating additional mechanisms leading to increased Ang II production 
[78]. Cardiac intrinsic angiotensin pathways are upregulated in HF progression 
mainly through increased ACE/ACE2 ratio, leading to excessive Ang II production 
and through activation of intracellular chymase-dependent axis responsible for 
additional Ang II production [53, 79]. Both of these pathways lead to cardiac Ang II 
generation and AT1R stimulation.
Indeed, apart from ACE the second major cardiac intrinsic mechanism  leading 
to excessive Ang II production in course of HF utilizes an intracellular source of 
Ang-(1–12) and chymase (present in different cell types, including mast cells, 
cardiac fibroblasts, and vascular endothelial cells [87, 88]). In HF, chymase-
dependent conversion of Ang-(1–12) to Ang II [4, 62, 89–91] was proposed to play 
a role of an independent intracrine pathway accounting for trophic, contractile, 
and pro-arrhythmic effects of Ang II in the human heart as well as in resistance 
arteries [92]. Interestingly, it was shown that MR antagonists decrease Ang-(1–12) 
 production and by this may additionally decrease the detrimental effects of Ang II 
[14]. The combined inhibition of chymase and ACE compared to ACE  inhibition 
alone provided an added benefit in terms of left ventricular function and adverse 
cardiac remodeling [93, 94]. Chymase-specific inhibitor improved cardiac  function 
in human myocardial infarction (MI) [95] and significantly  attenuated cardiac 
diastolic dysfunction accompanied by fibrosis in an experimental dog model of 
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tachycardiac-induced HF [96]. There is also evidence for local  (intracellular) 
 chymase activity that generates Ang II in the vascular wall [73, 95]. In relation 
to ACE, chymase is much more specific in Ang II production and does not break 
down bradykinin [87, 88, 97]. In contrast to ACE, chymase is not present in 
plasma and contributes only to tissue-based angiotensin pathways [87]. There is 
evidence for ACE inhibition-dependent chymase activation, which may explain 
a secondary increase in Ang II level in a large group of patients treated with 
ACE-I [93, 98].
In contrast to ACE and chymase, ACE2 has cardioprotective effects (influencing 
left ventricle remodeling and function) in HF [80]. In turn, loss of ACE2 leads to 
deterioration of cardiac function [81] and deleterious effects linked to increased 
Ang II production [49]. The ACE2 activity may be regulated by cardiac sheddases, 
which are located near ACE2 in the cellular membrane and their activation results 
in the secretion of a soluble form of tissue ACE2 into the circulation and decreases 
its activity in the heart. ADAM 17 (known as TACE) was proposed to act as a local 
sheddase [82, 83]. In humans, there are 21 sheddases described, among them 13 are 
proteolytically active [84], suggesting that besides ADAM 17 there may be other 
sheddases involved in ACE2 regulation. Shedding of ACE2 may be stimulated by 
Ang II acting through AT1R, which induces phosphorylation and activation of 
ADAM 17. Circulating soluble form of ACE2 was recognized as one of the markers 
of worsening HF prognosis [85, 86] that, in our opinion, might reflect the increased 
shedding of ACE2 from the heart and dominance of ACE/Ang II/AT1 axis in the 
heart.
In our recent study [99], in a unique murine model of HF that is character-
ized by a long-term development of end-stage HF [100], we demonstrated that 
changes in the profile of systemic versus tissue angiotensin pathways seem 
independent of each other. As shown in Figure 3, a significant increase in local 
Ang-(1–7) and alamandine content in the heart and aorta was observed at the 
early stage of HF and was followed by a decrease of Ang-(1–7) and alamandine 
in the heart and in the aorta at the late HF stage with simultaneous increase 
in Ang-(1–12). We concluded that HF progression in this murine model of HF 
was associated with a pronounced activation of the local ACE/Ang II pathway 
that was counterbalanced by a prominent ACE2/Ang-(1–7) activation with 
distinct pattern of changes in ACE/ACE2 balance in plasma. We tempted to  
speculate that the dominance of ACE2/Ang-(1–7) over ACE/Ang II in the adaptive 
phase of HF may contribute to the late onset of apparent cardiac dysfunction in 
this model and the balance between ACE/Ang II and ACE2/Ang-(1–7) in favor 
of the first axis determines the progression to the end stage of heart failure. 
Interestingly, the balance between ACE/Ang II and ACE2/Ang-(1–7) seems to 
correspond with aldosterone plasma concentration, low in the early phase and 
increased at the end stage of HF in this model (unpublished data).
Up to 45% of patients with reduced ejection fraction present elevated plasma 
angiotensin II levels despite ACE-I and MRA therapy [101, 102]. Moreover, for 
heart failure patients, with preserved ejection fraction and diastolic disturbance 
(which form up to 40% of HF patients), ACE-I are much less effective [103]. Lack 
of sufficient effectiveness of ACE-I and MRA therapy seems to support the notion 
of an ACE-independent local angiotensin pathway that may independently regulate 
Ang II production as well as AT1R stimulation and may represent an important 
contributing mechanism to heart failure progression. Clearly, the Ang II-generating 
mechanisms in HF are not well-controlled by current therapy, and this is also one of 
the reasons why additional treatment with MRA is frequently required and highly 
effective in HF patients.
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5. Quantification of angiotensin peptides and clinical needs
To better understand the regulation of angiotensin pathways and its impact 
on aldosterone/mineralocorticoid receptor-dependent pathways, the reliable 
 quantification of endogenous angiotensin peptides is needed, in particular for 
angiotensins that are representatives of classical ACE/Ang II and nonclassical ACE2/
Ang-(1–7) pathways. As the physiological levels of angiotensin peptides in  biological 
samples are extremely low (fmol/mL in plasma or fmol/g tissue in organs), the 
Figure 3. 
Angiotensin profile in plasma, the heart, and the aorta in Tgαq*44 mice. Concentration of Ang-(1–12), Ang-
(1–10), and Ang-(1–9) (a), Ang II, Ang III and Ang IV (b), Ang A, Ang-(1–7), and alamandine (c) in plasma, 
aorta, and heart homogenates. *P < 0.05 for the heart tissue of a given group of Tgαq*44 mice vs. 2-month-old 
Tgαq*44 mice; #P < 0.05 for the aorta tissue of a given Tgαq*44 group vs. 2-month-old Tgαq*44 mice; +P < 0.05 
for plasma of a given Tgαq*44 group vs. 2-month-old Tgαq*44 mice (one-way ANOVA with Tukey post hoc test 
or Kruskal-Wallis); δP < 0.05 hearts vs. plasma (t-test or Wilcoxon test). Reprinted with permission from [99].
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analytical approaches require very sensitive methods among which enzyme-linked 
immunosorbent assay (ELISA), radioimmunoassay (RIA), and liquid  
chromatography combined with RIA (LC-RIA) or mass spectrometry detection 
(LC-MS) are used so far (Table 1).
Origin Angiotensin peptides (endogenous level in healthy 
subjects*)
Analytical 
approach
Ref.
Plasma
Mouse Ang II (24–215 fmol); Ang-(1–7) (ca. 142 fmol) ELISA [109, 110]
Ang I (20–328 fmol); Ang II (15–48 fmol) LC-RIA [99, 111]
Alamandine (40–263 fmol); Ang I (57–180 fmol)
Ang II (28–86 fmol); Ang III (50–176 fmol)
Ang IV (35–118 fmol); Ang A (10–50 fmol)
Ang-(1–12) (8–75 fmol); Ang-(1–9) (8–46 fmol)
Ang-(1–7) (23–72 fmol)
LC-MS [99, 106]
Rat Ang II (72–95 pmol) ELISA [112, 113]
Ang I (40–137 fmol); Ang II (25–130 fmol) RIA [114, 115]
Ang I (10–130 fmol); Ang II (5–30 fmol)
Ang III (4–8 fmol); Ang IV (2.5–7 fmol)
Ang-(2–10) (26–70 fmol); Ang-(1–9) (2–6 fmol)
Ang-(3–10) (5–30 fmol); Ang-(1–7) (1.4–15 fmol)
Ang-(2–7) (2.6–7 fmol); Ang-(3–7) (ca. 8 fmol)
Ang-(4–8) (ca. 8 fmol)
LC-RIA [116–120]
Human Ang-(4–10) (ca. 16 fmol); Ang-(5–10) (ca. 80 fmol)
Ang-(6–10) (ca. 12 nmol)
FLD-EIA [121]
Ang II (ca. 18 fmol) LC-MS [122]
Ang I (ca. 20 fmol); Ang II (ca. 14 fmol)
Ang III (ca. 3.0 fmol); Ang-(1–9) (<0.4 fmol)
Ang-(2–10) (ca. 2.4 fmol); Ang-(2–9) (<2.1 fmol)
Ang-(1–7) (1.0–9.5 fmol); Ang-(2–7) (<1.1 fmol)
LC-RIA [123, 124]
Serum
Rat Ang II (42–87 fmol); Ang-(1–7) (2220–6310 fmol) CZE-PDA [125]
Urine
Rat Ang I (ca. 0.5 pmol); Ang II (ca. 1.25 pmol)
Ang-(1–7) (ca. 0.5 pmol)
RIA [115]
Human Ang-(1–7) (ca. 0.11 pmol) LC-RIA [126]
Kidney
Mouse Ang I (60–184 fmol); Ang II (159–328 fmol) LC-RIA [111, 127]
Rat Ang I (52–1050 fmol); Ang II (90–250 fmol)
Ang III (ca. 50 fmol); Ang IV (ca. 6 fmol)
Ang-(1–9) (ca. 64 fmol); Ang-(2–10) (ca. 300 fmol)
Ang-(3–10) (ca. 90 fmol); Ang-(1–7) (24–120 fmol)
Ang-(2–7) (ca. 50 fmol)
LC-RIA [117, 118, 128]
Adrenal gland
Mouse Ang I (ca. 7 fmol); Ang II (ca. 300 fmol) LC-RIA [111]
Rat Ang I (6–180 fmol); Ang II (545–2000 fmol)
Ang III (ca. 150 fmol); Ang IV (ca. 10 fmol)
Ang-(1–9) (<62 fmol); Ang-(2–10) (3–80 fmol)
Ang-(3–10) (ca. 3 fmol); Ang-(1–7) (30–180 fmol)
Ang-(2–7) (15–40 fmol); Ang-(3–7) (ca. 90 fmol)
LC-RIA [117, 118, 128]
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The immunoassay-based methods have many drawbacks, among others, 
being the lack of specific antibodies as the antibodies used currently in ELISA 
kits for Ang II quantification cross-react with Ang III (36–100%), Ang IV 
Origin Angiotensin peptides (endogenous level in healthy 
subjects*)
Analytical 
approach
Ref.
Lungs
Mouse Ang I (ca. 5 fmol); Ang II (ca. 90 fmol) LC-RIA [111]
Rat Ang I (2–3 fmol); Ang II (70–90 fmol)
Ang-(1–9) (ca. 4.6 fmol); Ang-(1–7) (<4.4 fmol)
LC-RIA [117, 128]
Liver
Mouse Ang I (1.9–39 fmol); Ang II (42–204 fmol) LC-RIA [127]
Heart
Mouse Ang I (5.3–36 fmol); Ang II (49–201fmol) LC-RIA [111, 127]
Alamandine (70–320 fmol); Ang I (5–50 fmol)
Ang II (10–100 fmol); Ang III (50–150 fmol)
Ang IV (15–35 fmol); Ang A (25–55 fmol)
Ang-(1–12) (20–280 fmol); Ang-(1–9) (35–50 fmol)
Ang-(1–7) (125–330 fmol)
LC-MS [99, 106]
Rat Ang I (5–25 fmol); Ang II (6–20 fmol);  
Ang III (ca. 5 fmol); Ang IV (ca. 1 fmol);  
Ang-(1–9) (<3.8 fmol)
Ang-(2–10) (ca. 2.5 fmol); Ang-(3–10) (ca. 2 fmol)
Ang-(1–7) (3.5–8 fmol); Ang-(2–7) (ca. 5 fmol)
LC-RIA [117, 120, 128]
Brain
Mouse Ang I (ca. 2 fmol); Ang II (ca. 5 fmol) LC-RIA [111]
Rat Ang I (<4 fmol); Ang II (8–16 fmol)
Ang-(1–9) (ca. 20 fmol); Ang-(1–7) (<13 fmol)
LC-RIA [117, 128]
Rat 
(medulla)
Ang I (1.5–520 fmol); Ang II (3–900 fmol)
Ang III (ca. 3 fmol); Ang IV (ca. 90 fmol)
Ang-(2–10) (1.2–80 fmol); Ang-(3–10) (1.4–45 fmol)
Ang-(1–7) (5–720 fmol); Ang-(2–7) (ca. 7 fmol)
Ang-(3–7) (ca. 180 fmol)
LC-RIA [116, 120]
Aorta
Mouse Alamandine (ca. 185 fmol); Ang I (ca. 16 fmol)
Ang II (ca. 15 fmol); Ang III (ca. 122 fmol)
Ang IV (ca. 30 fmol); Ang A (ca. 52 fmol)
Ang-(1–12) (ca. 57 fmol); Ang-(1–9) (ca. 25 fmol)
Ang-(1–7) (ca. 240 fmol)
LC-MS [99]
Rat Ang I (<10 fmol); Ang II (76–200 fmol)
Ang-(1–9) (<19 fmol); Ang-(1–7) (<20 fmol)
LC-RIA [117, 128]
Adipose
Rat (BAT) Ang I (ca. 8 fmol); Ang II (42–60 fmol)
Ang-(1–9) (ca. 8 fmol); Ang-(1–7) (<8 fmol)
LC-RIA [117, 128]
Rat (WAT) Ang II (18–56 pmol); Ang-(1–7) (190–648 pmol) CZE-PDA [125]
*The range of Ang peptides endogenous levels in healthy subjects was roughly estimated based on published data 
and expressed per milliliter (mL) of plasma, per mg of creatinine excreted per day for urine, and per g of tissue 
for organs; BAT, brown adipose tissue; WA, white adipose tissue; LC-RI, liquid chromatography combined with 
radioimmunoassay; LC-MS, liquid chromatography combined with mass spectrometry; RIA, radioimmunoassay; 
FLD-EIA, immunofluorescence assay; CZE-PDA, capillary zone electrophoresis with PDA detection.
Table 1. 
The range of endogenous levels of angiotensin peptides in various biological matrices and the most commonly 
used analytical approaches for their quantification.
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(33–100%), and Ang A (100%) which leads to the overestimation of the real 
concentration of Ang II in measured samples and does not allow to discern the 
role of individual angiotensin peptides. The limitations of immunoassay-based 
approaches are overcome by a highly specific, sensitive LC-MS technique. As 
LC-MS relies on the initial identification of studied peptides based on their 
molecular weight followed by detection of peptide fragmentation signatures, 
this approach is highly specific for individual angiotensins [105, 106]. Indeed, 
in a number of studies including our own [99, 106–108], LC-MS enabled a 
 comprehensive analysis of various angiotensin peptides in in vivo, in vitro, and 
ex vivo studies (Table 1).
It seems that the pattern of Ang peptides measured in plasma could be of 
the clinical value and LC-MS could offer adequate analytical potential to  foster 
 development of angiotensin profiling in clinical field. After optimization, 
 introduction of such analyses into the clinic may provide fundamental information 
in many current clinical challenges such as treatment of resistant hypertension or 
reversal of pathological cardiac remodeling. At the same time, angiotensin  profiling 
could lead to a better understanding of upstream mechanisms of classical and 
nonclassical pathways of RAAS in the regulation of aldosterone/mineralocorticoid 
receptor-dependent pathways.
6. Conclusion
The diverse role of the aldosterone/mineralocorticoid receptor-dependent 
pathway in physiology and pathology needs to be analyzed in the context of the 
increasingly complex network of angiotensins. In fact a number of noncanonical 
mechanisms of angiotensin pathways represent possible novel upstream targets 
to inhibit aldosterone/mineralocorticoid receptor-dependent pathways, for 
example, the ACE2/Ang-(1–7) pathway and their novel regulatory elements such 
as sheddases (ADAM 17) or apelin (which increases ACE2 promotor activity) 
[129], as well as Ang-(1–12)/chymase/Ang II pathway. As expected,  interventions 
blocking Ang-(1–12)/chymase/Ang II as well as enhancing ACE2/Ang-(1–7) 
diminished aldosterone production [124, 130]. It remains to be determined, 
however, which of the novel pharmacotherapies, shown to be effective in 
experimental heart failure including chymase inhibitors [131], recombinant 
human ACE2 [132–134], Ang-(1–7) [135], or combined angiotensin receptor 
antagonist and neprilysin inhibitor (ARNI) [104], are most effective in reducing 
the  activity of aldosterone/mineralocorticoid receptor-dependent signaling. To 
exploit further these novel mechanisms pharmacotherapeutically, it is important 
to better understand the heterogeneity of local angiotensin pathways in various 
organs and their effects on aldosterone/mineralocorticoid receptor-dependent 
pathways.
Finally, we believe that the profiling of angiotensins in clinical facilities, at least 
for these two angiotensins (i.e., Ang II, Ang-(1–7)) with opposite actions on MR 
and aldosterone production, may prove to be a good tool to optimize the pharmaco-
therapy of RAAS including treatment with MRA.
Acknowledgements
This publication is based upon work from the EU COST Action ADMIRE 
BM1301 in aldosterone and mineralocorticoid receptor (MR) physiology and 
pathophysiology (www.admirecosteu.com).
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
12
© 2019 The Author(s). Licensee IntechOpen. Distributed under the terms of the Creative 
Commons Attribution - NonCommercial 4.0 License (https://creativecommons.org/
licenses/by-nc/4.0/), which permits use, distribution and reproduction for  
non-commercial purposes, provided the original is properly cited. 
Author details
Urszula Tyrankiewicz1, Agnieszka Kij1, Tasnim Mohaissen1, Mariola Olkowicz2, 
Ryszard T. Smolenski3 and Stefan Chlopicki1,4*
1 Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
Krakow, Poland
2 Department of Chemistry, University of Waterloo, Waterloo, Ontario, Canada
3 Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland
4 Chair of Pharmacology, Jagiellonian University Medical College, Krakow, Poland
*Address all correspondence to: stefan.chlopicki@jcet.eu
13
Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin…
DOI: http://dx.doi.org/10.5772/intechopen.87239
References
[1] Patel S, Rauf A, Khan H,  
Abu-Izneid T. Renin-angiotensin-
aldosterone (RAAS): The ubiquitous 
system for homeostasis and pathologies. 
Biomedicine & Pharmacotherapy. 
2017;94:317-325
[2] Tipnis SR, Hooper NM, Hyde R, 
Karran E, Christie G, Turner AJ. A 
human homolog of angiotensin-
converting enzyme. Cloning and 
functional expression as a captopril-
insensitive carboxypeptidase. 
Journal of Biological Chemistry. 
2000;275(43):33238-33243
[3] Donoghue M, Hsieh F, Baronas E, 
Godbout K, Gosselin M, Stagliano N, 
et al. A novel angiotensin-converting 
enzyme-related carboxypeptidase 
(ACE2) converts angiotensin I to 
angiotensin 1-9. Circulation Research. 
2000;87(5):E1-E9
[4] Ahmad S, Varagic J, Groban L, 
Dell'Italia LJ, Nagata S, Kon ND, et al. 
Angiotensin-(1-12): A chymase-
mediated cellular angiotensin II 
substrate. Current Hypertension 
Reports. 2014;16(5):429
[5] Holappa M, Vapaatalo H, 
Vaajanen A. Many faces of renin-
angiotensin system—Focus on 
eye. Open Ophthalmology Journal. 
2017;11:122-142
[6] Milliez P, Girerd X, Plouin PF, 
Blacher J, Safar ME, Mourad JJ. 
Evidence for an increased rate of 
cardiovascular events in patients with 
primary aldosteronism. Journal of 
the American College of Cardiology. 
2005;45(8):1243-1248
[7] Andreozzi F, Laratta E, Sciacqua A, 
Perticone F, Sesti G. Angiotensin II 
impairs the insulin signaling pathway 
promoting production of nitric oxide 
by inducing phosphorylation of insulin 
receptor substrate-1 on Ser(312) and 
Ser(616) in human umbilical vein 
endothelial cells. Circulation Research. 
2004;94(9):1211-1218
[8] Nakashima H, Suzuki H, Ohtsu H, 
Chao JY, Utsunomiya H, Frank GD, 
et al. Angiotensin II regulates vascular 
and endothelial dysfunction: Recent 
topics of angiotensin II type-1 
receptor signaling in the vasculature. 
Current Vascular Pharmacology. 
2006;4(1):67-78
[9] Kawai T, Forrester SJ, O'Brien S, 
Baggett A, Rizzo V, Eguchi S. AT1 
receptor signaling pathways in the 
cardiovascular system. Pharmacological 
Research. 2017;125(Pt A):4-13
[10] Miyata K, Rahman M, Shokoji T, 
Nagai Y, Zhang GX, Sun GP, et al. 
Aldosterone stimulates reactive 
oxygen species production through 
activation of NADPH oxidase in 
rat mesangial cells. Journal of the 
American Society of Nephrology. 
2005;16(10):2906-2912
[11] Munzel T, Gori T, Keaney JF Jr, 
Maack C, Daiber A. Pathophysiological 
role of oxidative stress in systolic and 
diastolic heart failure and its therapeutic 
implications. European Heart Journal. 
2015;36(38):2555-2564
[12] Keidar S, Gamliel-Lazarovich A, 
Kaplan M, Pavlotzky E, Hamoud S, 
Hayek T, et al. Mineralocorticoid 
receptor blocker increases 
angiotensin-converting enzyme 2 
activity in congestive heart failure 
patients. Circulation Research. 
2005;97(9):946-953
[13] Kong EL, Zhang JM, An N, Tao Y, 
Yu WF, Wu FX. Spironolactone rescues 
renal dysfunction in obstructive 
jaundice rats by upregulating 
ACE2 expression. Journal of Cell 
Communication and Signaling. 
2019;13(1):17-26
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
14
[14] Whaley-Connell A, Habibi J, Wei Y, 
Gutweiler A, Jellison J, Wiedmeyer CE, 
et al. Mineralocorticoid receptor 
antagonism attenuates glomerular 
filtration barrier remodeling in the 
transgenic Ren2 rat. American Journal 
of Physiology. Renal Physiology. 
2009;296(5):F1013-F1022
[15] Kucharewicz I, Pawlak R, Matys T, 
Pawlak D, Buczko W. Antithrombotic 
effect of captopril and losartan is 
mediated by angiotensin-(1-7). 
Hypertension. 2002;40(5):774-779
[16] Kaiqiang J, Minakawa M, Fukui K, 
Suzuki Y, Fukuda I. Olmesartan 
improves left ventricular function 
in pressure-overload hypertrophied 
rat heart by blocking angiotensin 
II receptor with synergic effects 
of upregulation of angiotensin 
converting enzyme 2. Therapeutic 
Advances in Cardiovascular Disease. 
2009;3(2):103-111
[17] Sukumaran V, Veeraveedu PT, 
Gurusamy N, Yamaguchi K, 
Lakshmanan AP, Ma ML, et al. 
Cardioprotective effects of telmisartan 
against heart failure in rats induced by 
experimental autoimmune myocarditis 
through the modulation of angiotensin-
converting enzyme-2/angiotensin 
1-7/Mas receptor axis. International 
Journal of Biological Sciences. 
2011;7(8):1077-1092
[18] Wang XX, Ye Y, Gong H, Wu J, 
Yuan J, Wang SJ, et al. The effects of 
different angiotensin II type 1 receptor 
blockers on the regulation of the 
ACE-AngII-AT1 and ACE2-Ang(1-7)-
Mas axes in pressure overload-induced 
cardiac remodeling in male mice. 
Journal of Molecular and Cellular 
Cardiology. 2016;97:180-190
[19] Zhong JC, Ye JY, Jin HY, Yu X, 
Yu HM, Zhu DL, et al. Telmisartan 
attenuates aortic hypertrophy 
in hypertensive rats by the 
modulation of ACE2 and profilin-1 
expression. Regulatory Peptides. 
2011;166(1-3):90-97
[20] Ishiyama Y, Gallagher PE, 
Averill DB, Tallant EA, Brosnihan 
KB, Ferrario CM. Upregulation of 
angiotensin-converting enzyme 2 after 
myocardial infarction by blockade of 
angiotensin II receptors. Hypertension. 
2004;43(5):970-976
[21] Harada E, Yoshimura M, Yasue H, 
Nakagawa O, Nakagawa M, Harada M, 
et al. Aldosterone induces angiotensin-
converting-enzyme gene expression 
in cultured neonatal rat cardiocytes. 
Circulation. 2001;104(2):137-139
[22] Itcho K, Oki K, Kobuke K, Ohno H, 
Yoneda M, Hattori N. Angiotensin 1-7 
suppresses angiotensin II mediated 
aldosterone production via JAK/STAT 
signaling inhibition. The Journal of 
Steroid Biochemistry and Molecular 
Biology. 2019;185:137-141
[23] Chen Y, Zhao W, Liu C, Meng W, 
Zhao T, Bhattacharya SK, et al. 
Molecular and cellular effect of 
angiotensin 1-7 on hypertensive 
kidney disease. American Journal of 
Hypertension. 2019;32(5):460-467
[24] Galandrin S, Denis C, Boularan C, 
Marie J, M'Kadmi C, Pilette C, et al. 
Cardioprotective angiotensin-(1-7) 
peptide acts as a natural-biased ligand 
at the angiotensin II type 1 receptor. 
Hypertension. 2016;68(6):1365-1374
[25] Gavras H, Lever AF, Brown JJ, 
Macadam RF, Robertson JI. Acute 
renal failure, tubular necrosis, and 
myocardial infarction induced in the 
rabbit by intravenous angiotensin 
II. Lancet. 1971;2(7714):19-22
[26] Ikeda Y, Nakamura T, Takano H, 
Kimura H, Obata JE, Takeda S, et al. 
Angiotensin II-induced cardiomyocyte 
hypertrophy and cardiac fibrosis 
15
Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin…
DOI: http://dx.doi.org/10.5772/intechopen.87239
in stroke-prone spontaneously 
hypertensive rats. The Journal of 
Laboratory and Clinical Medicine. 
2000;135(4):353-359
[27] Daugherty A, Cassis L. Chronic 
angiotensin II infusion promotes 
atherogenesis in low density lipoprotein 
receptor −/− mice. Annals of the 
New York Academy of Sciences. 
1999;892:108-118
[28] Karnik SS, Unal H, Kemp JR, 
Tirupula KC, Eguchi S, Vanderheyden 
PM, et al. International Union of 
Basic and Clinical Pharmacology. 
XCIX. Angiotensin receptors: 
Interpreters of pathophysiological 
angiotensinergic stimuli [corrected]. 
Pharmacological Reviews. 
2015;67(4):754-819
[29] Kaschina E, Namsolleck P, Unger T. 
AT2 receptors in cardiovascular 
and renal diseases. Pharmacological 
Research. 2017;125(Pt A):39-47
[30] Singh KD, Karnik SS. Angiotensin 
receptors: Structure, function, signaling 
and clinical applications. Journal of Cell 
Signalling. 2016;1(2)
[31] Skorska A, von Haehling S, 
Ludwig M, Lux CA, Gaebel R, 
Kleiner G, et al. The CD4(+)AT2R(+) 
T cell subpopulation improves 
post-infarction remodelling and 
restores cardiac function. Journal of 
Cellular and Molecular Medicine. 
2015;19(8):1975-1985
[32] Zhu LP, Carretero OA, Xu J, 
Harding P, Ramadurai N, Gu XS, et al. 
Activation of angiotensin II type 2 
receptor suppresses TNF-alpha-induced 
ICAM-1 via NF-kappa B: Possible role of 
ACE2. American Journal of Physiology-
Heart and Circulatory Physiology. 
2015;309(5):H827-H834
[33] Tanaka M, Tsuchida S, Imai T, Fujii 
N, Miyazaki H, Ichiki T, et al. Vascular 
response to angiotensin II is exaggerated 
through an upregulation of AT1 receptor 
in AT2 knockout mice. Biochemical and 
Biophysical Research Communications. 
1999;258(1):194-198
[34] Bedecs K, Elbaz N, Sutren M, 
Masson M, Susini C, Strosberg AD, et al. 
Angiotensin II type 2 receptors mediate 
inhibition of mitogen-activated protein 
kinase cascade and functional activation 
of SHP-1 tyrosine phosphatase. The 
Biochemical Journal. 1997;325(Pt 2): 
449-454
[35] AbdAlla S, Lother H, Abdel-Tawab 
AM, Quitterer U. The angiotensin II AT2 
receptor is an AT1 receptor antagonist. 
The Journal of Biological Chemistry. 
2001;276(43):39721-39726
[36] de Gasparo M, Catt KJ, Inagami T, 
Wright JW, Unger T. International 
Union of Pharmacology. XXIII. 
The angiotensin II receptors. 
Pharmacological Reviews. 
2000;52(3):415-472
[37] Jones ES, Vinh A, McCarthy CA, 
Gaspari TA, Widdop RE. AT2 receptors: 
Functional relevance in cardiovascular 
disease. Pharmacology & Therapeutics. 
2008;120(3):292-316
[38] Cook JL, Mills SJ, Naquin R, Alam J, 
Re RN. Nuclear accumulation of the 
AT1 receptor in a rat vascular smooth 
muscle cell line: Effects upon signal 
transduction and cellular proliferation. 
Journal of Molecular and Cellular 
Cardiology. 2006;40(5):696-707
[39] Cook JL, Mills SJ, Naquin RT, 
Alam J, Re RN. Cleavage of the 
angiotensin II type 1 receptor and 
nuclear accumulation of the cytoplasmic 
carboxy-terminal fragment. American 
Journal of Physiology. Cell Physiology. 
2007;292(4):C1313-C1322
[40] Cook JL, Re R, Alam J, Hart M, 
Zhang Z. Intracellular angiotensin 
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
16
II fusion protein alters AT1 receptor 
fusion protein distribution and activates 
CREB. Journal of Molecular and Cellular 
Cardiology. 2004;36(1):75-90
[41] Villela DC, Passos-Silva DG, 
Santos RA. Alamandine: A new 
member of the angiotensin family. 
Current Opinion in Nephrology and 
Hypertension. 2014;23(2):130-134
[42] Keidar S, Kaplan M, Gamliel-
Lazarovich A. ACE2 of the heart: 
From angiotensin I to angiotensin 
(1-7). Cardiovascular Research. 
2007;73(3):463-469
[43] Santos RA, Simoes e Silva AC, 
Maric C, Silva DM, Machado RP, de 
Buhr I, et al. Angiotensin-(1-7) is an 
endogenous ligand for the G protein-
coupled receptor Mas. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2003;100(14):8258-8263
[44] Menon J, Soto-Pantoja DR, 
Callahan MF, Cline JM, Ferrario CM, 
Tallant EA, et al. Angiotensin-(1-7) 
inhibits growth of human lung 
adenocarcinoma xenografts in 
nude mice through a reduction in 
cyclooxygenase-2. Cancer Research. 
2007;67(6):2809-2815
[45] Lautner RQ , Villela DC, Fraga-
Silva RA, Silva N, Verano-Braga T, 
Costa-Fraga F, et al. Discovery and 
characterization of alamandine: A novel 
component of the renin-angiotensin 
system. Circulation Research. 
2013;112(8):1104-1111
[46] Dias-Peixoto MF, Santos RA, 
Gomes ER, Alves MN, Almeida PW, 
Greco L, et al. Molecular mechanisms 
involved in the angiotensin-(1-7)/Mas 
signaling pathway in cardiomyocytes. 
Hypertension. 2008;52(3):542-548
[47] Zhong J, Basu R, Guo D, 
Chow FL, Byrns S, Schuster M, 
et al. Angiotensin-converting 
enzyme 2 suppresses pathological 
hypertrophy, myocardial fibrosis, 
and cardiac dysfunction. Circulation. 
2010;122(7):717-728, 18 p following 728
[48] Sampaio WO, Souza dos 
Santos RA, Faria-Silva R, da Mata 
Machado LT, Schiffrin EL, Touyz RM. 
Angiotensin-(1-7) through receptor 
Mas mediates endothelial nitric 
oxide synthase activation via Akt-
dependent pathways. Hypertension. 
2007;49(1):185-192
[49] Patel VB, Zhong JC, Grant MB, 
Oudit GY. Role of the ACE2/angiotensin 
1-7 axis of the renin-angiotensin system 
in heart failure. Circulation Research. 
2016;118(8):1313-1326
[50] Kozlovski VI, Lomnicka M, 
Bartus M, Sternak M, Chlopicki S. 
Anti-thrombotic effects of nebivolol 
and carvedilol: Involvement of 
beta2 receptors and COX-2/PGI2 
pathways. Pharmacological Reports. 
2015;67(5):1041-1047
[51] Dales NA, Gould AE, Brown JA, 
Calderwood EF, Guan B, Minor CA, 
et al. Substrate-based design of the 
first class of angiotensin-converting 
enzyme-related carboxypeptidase 
(ACE2) inhibitors. Journal of 
the American Chemical Society. 
2002;124(40):11852-11853
[52] Gallagher PE, Ferrario CM, 
Tallant EA. Regulation of ACE2 in 
cardiac myocytes and fibroblasts. 
American Journal of Physiology. 
Heart and Circulatory Physiology. 
2008;295(6):H2373-H2379
[53] Weber KT, Sun Y. Recruitable ACE 
and tissue repair in the infarcted heart. 
Journal of the Renin-Angiotensin-
Aldosterone System. 2000;1(4):295-303
[54] Li XC, Zhang JF, Zhuo 
JL. The vasoprotective axes of the 
17
Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin…
DOI: http://dx.doi.org/10.5772/intechopen.87239
renin-angiotensin system: Physiological 
relevance and therapeutic implications 
in cardiovascular, hypertensive and 
kidney diseases. Pharmacological 
Research. 2017;125:21-38
[55] Saris JJ, ’t Hoen PA, Garrelds IM, 
Dekkers DH, den Dunnen JT, Lamers 
JM, et al. Prorenin induces intracellular 
signaling in cardiomyocytes 
independently of angiotensin 
II. Hypertension. 2006;48(4):564-571
[56] Zhuo JL, Ferrao FM, Zheng Y, 
Li XC. New frontiers in the intrarenal 
renin-angiotensin system: A critical 
review of classical and new paradigms. 
Frontiers in Endocrinology (Lausanne). 
2013;4:166
[57] Blair-West JR, Carey KD, 
Denton DA, Madden LJ, Weisinger RS, 
Shade RE. Possible contribution of 
brain angiotensin III to ingestive 
behaviors in baboons. American 
Journal of Physiology. Regulatory, 
Integrative and Comparative Physiology. 
2001;281(5):R1633-R1636
[58] Zulli A, Burrell LM, Buxton BF, 
Hare DL. ACE2 and AT4R are present 
in diseased human blood vessels. 
European Journal of Histochemistry. 
2008;52(1):39-44
[59] Ferrario CM, Ahmad S, Varagic J, 
Cheng CP, Groban L, Wang H, et al. 
Intracrine angiotensin II functions 
originate from noncanonical pathways 
in the human heart. American Journal 
of Physiology. Heart and Circulatory 
Physiology. 2016;311(2):H404-H414
[60] Isa K, Garcia-Espinosa MA, Arnold 
AC, Pirro NT, Tommasi EN, Ganten D, 
et al. Chronic immunoneutralization 
of brain angiotensin-(1-12) lowers 
blood pressure in transgenic (mRen2)27 
hypertensive rats. American Journal 
of Physiology. Regulatory, Integrative 
and Comparative Physiology. 
2009;297(1):R111-R115
[61] Urata H, Hoffmann S, Ganten D. 
Tissue angiotensin II system in the 
human heart. European Heart Journal. 
1994;15(Suppl D):68-78
[62] Jessup JA, Trask AJ, Chappell MC, 
Nagata S, Kato J, Kitamura K, et al. 
Localization of the novel angiotensin 
peptide, angiotensin-(1-12), in heart 
and kidney of hypertensive and 
normotensive rats. American Journal 
of Physiology. Heart and Circulatory 
Physiology. 2008;294(6):H2614-H2618
[63] McDonald JE, Padmanabhan N, 
Petrie MC, Hillier C, Connell JM, 
McMurray JJ. Vasoconstrictor effect of 
the angiotensin-converting enzyme-
resistant, chymase-specific substrate 
[pro(11)(D)-Ala(12)] angiotensin I 
in human dorsal hand veins: in vivo 
demonstration of non-ace production of 
angiotensin II in humans. Circulation. 
2001;104(15):1805-1808
[64] Stephenson SL, Kenny AJ. The 
metabolism of neuropeptides. 
Hydrolysis of peptides by the 
phosphoramidon-insensitive rat kidney 
enzyme 'endopeptidase-2′ and by rat 
microvillar membranes. Biochemical 
Journal. 1988;255(1):45-51
[65] Patil J, Stucki S, Nussberger J, 
Schaffner T, Gygax S, Bohlender J, et al. 
Angiotensinergic and noradrenergic 
neurons in the rat and human heart. 
Regulatory Peptides. 2011;167(1):31-41
[66] Uehara Y, Urata H, Ideishi M, 
Arakawa K, Saku K. Chymase inhibition 
suppresses high-cholesterol diet-
induced lipid accumulation in the 
hamster aorta. Cardiovascular Research. 
2002;55(4):870-876
[67] Borges JC, Silva JA Jr, Gomes MA, 
Lomez ES, Leite KM, Araujo RC, et al. 
Tonin in rat heart with experimental 
hypertrophy. American Journal of 
Physiology. Heart and Circulatory 
Physiology. 2003;284(6):H2263-H2268
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
18
[68] Welches WR, Brosnihan KB, 
Ferrario CM. A comparison of the 
properties and enzymatic-activities of 
3 angiotensin processing enzymes—
Angiotensin-converting enzyme, 
prolyl endopeptidase and neutral 
endopeptidase 24.11. Life Sciences. 
1993;52(18):1461-1480
[69] Allred AJ, Diz DI, Ferrario CM, 
Chappell MC. Pathways for 
angiotensin-(1-7) metabolism in 
pulmonary and renal tissues. American 
Journal of Physiology-Renal Physiology. 
2000;279(5):F841-F850
[70] Campbell DJ, Anastasopoulos F, 
Duncan AM, James GM, Kladis A, 
Briscoe TA. Effects of neutral 
endopeptidase inhibition and combined 
angiotensin converting enzyme and 
neutral endopeptidase inhibition on 
angiotensin and bradykinin peptides 
in rats. The Journal of Pharmacology 
and Experimental Therapeutics. 
1998;287(2):567-577
[71] Chappell MC, Gomez MN, 
Pirro NT, Ferrario CM. Release of 
angiotensin-(1-7) from the rat hindlimb: 
Influence of angiotensin-converting 
enzyme inhibition. Hypertension. 
2000;35(1 Pt 2):348-352
[72] Ferrario CM. Contribution of 
angiotensin-(1-7) to cardiovascular 
physiology and pathology. 
Current Hypertension Reports. 
2003;5(2):129-134
[73] Jeong JK, Diano S. Prolyl 
carboxypeptidase and its inhibitors in 
metabolism. Trends in Endocrinology 
and Metabolism. 2013;24(2):61-67
[74] Ponikowski P, Voors AA, Anker SD, 
Bueno H, Cleland JG, Coats AJ, et al. R. 
Document, 2016 ESC Guidelines for 
the diagnosis and treatment of acute 
and chronic heart failure: The Task 
Force for the diagnosis and treatment 
of acute and chronic heart failure of the 
European Society of Cardiology (ESC). 
Developed with the special contribution 
of the Heart Failure Association (HFA) 
of the ESC. European Journal of Heart 
Failure. 2016;18(8):891-975
[75] Dell'Italia LJ, Meng QC, Balcells E, 
Wei CC, Palmer R, Hageman GR, et al. 
Compartmentalization of angiotensin 
II generation in the dog heart. Evidence 
for independent mechanisms in 
intravascular and interstitial spaces. 
Journal of Clinical Investigation. 
1997;100(2):253-258
[76] de Lannoy LM, Danser AH, 
van Kats JP, Schoemaker RG, 
Saxena PR, Schalekamp MA. Renin-
angiotensin system components in 
the interstitial fluid of the isolated 
perfused rat heart. Local production 
of angiotensin I. Hypertension. 
1997;29(6):1240-1251
[77] Danser AHJ, Vankats JP, Admiraal 
PJJ, Derks FHM, Lamers JMJ, 
Verdouw PD, et al. Cardiac renin and 
angiotensins—Uptake from plasma 
versus in-situ synthesis. Hypertension. 
1994;24(1):37-48
[78] Barlucchi L, Leri A, Dostal DE, 
Fiordaliso F, Tada H, Hintze TH, 
et al. Canine ventricular myocytes 
possess a renin-angiotensin system 
that is upregulated with heart 
failure. Circulation Research. 
2001;88(3):298-304
[79] Ihara M, Urata H, Kinoshita A, 
Suzumiya J, Sasaguri M, Kikuchi M, 
et al. Increased chymase-dependent 
angiotensin II formation in human 
atherosclerotic aorta. Hypertension. 
1999;33(6):1399-1405
[80] Dong B, Yu QT, Dai HY, Gao YY, 
Zhou ZL, Zhang L, et al. Angiotensin-
converting enzyme-2 overexpression 
improves left ventricular remodeling 
and function in a rat model of 
diabetic cardiomyopathy. Journal of 
19
Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin…
DOI: http://dx.doi.org/10.5772/intechopen.87239
the American College of Cardiology. 
2012;59(8):739-747
[81] Kassiri Z, Zhong J, Guo D, 
Basu R, Wang X, Liu PP, et al. Loss 
of angiotensin-converting enzyme 2 
accelerates maladaptive left ventricular 
remodeling in response to myocardial 
infarction. Circulation. Heart Failure. 
2009;2(5):446-455
[82] Lambert DW, Yarski M, Warner FJ, 
Thornhill P, Parkin ET, Smith AI, et al. 
Tumor necrosis factor-alpha convertase 
(ADAM17) mediates regulated 
ectodomain shedding of the severe-
acute respiratory syndrome-coronavirus 
(SARS-CoV) receptor, angiotensin-
converting enzyme-2 (ACE2). The 
Journal of Biological Chemistry. 
2005;280(34):30113-30119
[83] Patel VB, Clarke N, Wang Z, Fan D, 
Parajuli N, Basu R, et al. Angiotensin 
II induced proteolytic cleavage of 
myocardial ACE2 is mediated by 
TACE/ADAM-17: A positive feedback 
mechanism in the RAS. Journal of 
Molecular and Cellular Cardiology. 
2014;66:167-176
[84] Edwards DR, Handsley MM, 
Pennington CJ. The ADAM 
metalloproteinases. Molecular Aspects 
of Medicine. 2008;29(5):258-289
[85] Putko BN, Wang Z, Lo J, 
Anderson T, Becher H, Dyck JR, et al. 
Circulating levels of tumor necrosis 
factor-alpha receptor 2 are increased 
in heart failure with preserved ejection 
fraction relative to heart failure with 
reduced ejection fraction: Evidence for 
a divergence in pathophysiology. PLoS 
One. 2014;9(6):e99495
[86] Uri K, Fagyas M, Kertesz A, 
Borbely A, Jenei C, Bene O, et al. 
Circulating ACE2 activity correlates with 
cardiovascular disease development. 
Journal of the Renin-Angiotensin-
Aldosterone System. 2016;17(4)
[87] Urata H, Kinoshita A, Misono KS, 
Bumpus FM, Husain A. Identification 
of a highly specific chymase as 
the major angiotensin II-forming 
enzyme in the human heart. The 
Journal of Biological Chemistry. 
1990;265(36):22348-22357
[88] Dell'Italia LJ, Collawn JF, 
Ferrario CM. Multifunctional role of 
chymase in acute and chronic tissue 
injury and remodeling. Circulation 
Research. 2018;122(2):319-336
[89] Ahmad S, Varagic J, VonCannon JL, 
Groban L, Collawn JF, Dell'Italia LJ, 
et al. Primacy of cardiac chymase over 
angiotensin converting enzyme as 
an angiotensin-(1-12) metabolizing 
enzyme. Biochemical and Biophysical 
Research Communications. 
2016;478(2):559-564
[90] Patella V, de Crescenzo G, 
Lamparter-Schummert B, De Rosa 
G, Adt M, Marone G. Increased 
cardiac mast cell density and mediator 
release in patients with dilated 
cardiomyopathy. Inflammation 
Research. 1997;46(Suppl 1):S31-S32
[91] Ferrario CM, Ahmad S, Nagata S, 
Simington SW, Varagic J, Kon N, et al. 
An evolving story of angiotensin-
II-forming pathways in rodents and 
humans. Clinical Science (London, 
England). 2014;126(7):461-469
[92] Petrie MC, Padmanabhan N, 
McDonald JE, Hillier C, Connell JMC, 
McMurray JJV. Angiotensin converting 
enzyme (ACE) and non-ACE dependent 
angiotensin II generation in resistance 
arteries from patients with heart failure 
and coronary heart disease. Journal of 
the American College of Cardiology. 
2001;37(4):1056-1061
[93] Wei CC, Hase N, Inoue Y, 
Bradley EW, Yahiro E, Li M, et al. 
Mast cell chymase limits the cardiac 
efficacy of Ang I-converting enzyme 
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
20
inhibitor therapy in rodents. The 
Journal of Clinical Investigation. 
2010;120(4):1229-1239
[94] Reyes S, Varagic J, Ahmad S, 
VonCannon J, Kon ND, Wang H, et al. 
Novel cardiac intracrine mechanisms 
based on Ang-(1-12)/chymase axis 
require a revision of therapeutic 
approaches in human heart disease. 
Current Hypertension Reports. 
2017;19(2):16
[95] Jin D, Takai S, Nonaka Y, 
Yamazaki S, Fujiwara M, Nakamura Y. 
A chymase inhibitory RNA aptamer 
improves cardiac function and survival 
after myocardial infarction. Molecular 
Therapy—Nucleic Acids. 2019;14:41-51
[96] Matsumoto T, Wada A, 
Tsutamoto T, Ohnishi M, Fujii M, 
Yamamoto T, et al. Chronic chymase 
inhibition prevented cardiac fibrosis 
and improved diastolic dysfunction 
in the progression of heart failure. 
Circulation. 2002;106(19):99-100
[97] Balcells E, Meng QC, Johnson WH 
Jr, Oparil S, Dell'Italia LJ. Angiotensin 
II formation from ACE and chymase in 
human and animal hearts: Methods and 
species considerations. The American 
Journal of Physiology. 1997;273(4 Pt 2): 
H1769-H1774
[98] Zablocki D, Sadoshima J. The one-
two punch: Knocking out angiotensin 
II in the heart. The Journal of Clinical 
Investigation. 2010;120(4):1028-1031
[99] Tyrankiewicz U, Olkowicz M, 
Skorka T, Jablonska M, Orzylowska A, 
Bar A, et al. Activation pattern of ACE2/
Ang-(1-7) and ACE/Ang II pathway 
in course of heart failure assessed 
by multiparametric MRI in vivo in 
Tgalphaq*44 mice. Journal of Applied 
Physiology. 1985, 2018;124(1):52-65
[100] Mackiewicz U, Czarnowska E, 
Brudek M, Pajak B, Duda M, 
Emanuel K, et al. Preserved 
cardiomyocyte function and altered 
desmin pattern in transgenic mouse 
model of dilated cardiomyopathy. 
Journal of Molecular and Cellular 
Cardiology. 2012;52(5):978-987
[101] Athyros VG, Mikhailidis 
DP, Kakafika AI, Tziomalos K, 
Karagiannis A. Angiotensin II 
reactivation and aldosterone escape 
phenomena in renin-angiotensin-
aldosterone system blockade: Is 
oral renin inhibition the solution? 
Expert Opinion on Pharmacotherapy. 
2007;8(5):529-535
[102] Juillerat L, Nussberger J, Menard J, 
Mooser V, Christen Y, Waeber B, 
et al. Determinants of angiotensin 
II generation during converting 
enzyme inhibition. Hypertension. 
1990;16(5):564-572
[103] Fukuta H, Goto T, Wakami K, 
Ohte N. Effect of renin-angiotensin 
system inhibitors on mortality in heart 
failure with preserved ejection fraction: 
A meta-analysis of observational 
cohort and randomized controlled 
studies. Heart Failure Reviews. 
2017;22(6):775-782
[104] Jhund PS, McMurray JJV. The 
neprilysin pathway in heart failure: 
A review and guide on the use 
of sacubitril/valsartan. Heart. 
2016;102(17):1342-1347
[105] Cui L, Nithipatikom K, 
Campbell WB. Simultaneous analysis 
of angiotensin peptides by LC-MS and 
LC-MS/MS: Metabolism by bovine 
adrenal endothelial cells. Analytical 
Biochemistry. 2007;369(1):27-33
[106] Olkowicz M, Chlopicki S, 
Smolenski RT. A primer to angiotensin 
peptide isolation, stability, and analysis 
by nano-liquid chromatography with 
mass detection. Methods in Molecular 
Biology. 2017;1614:175-187
21
Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin…
DOI: http://dx.doi.org/10.5772/intechopen.87239
[107] Olkowicz M, Debski J, Jablonska P, 
Dadlez M, Smolenski RT. Application 
of a new procedure for liquid 
chromatography/mass spectrometry 
profiling of plasma amino acid-related 
metabolites and untargeted shotgun 
proteomics to identify mechanisms 
and biomarkers of calcific aortic 
stenosis. Journal of Chromatography. A. 
2017;1517:66-78
[108] Olkowicz M, Radulska A, Suraj J, 
Kij A, Walczak M, Chlopicki S, et al. 
Development of a sensitive, accurate 
and robust liquid chromatography/mass 
spectrometric method for profiling 
of angiotensin peptides in plasma 
and its application for atherosclerotic 
mice. Journal of Chromatography. A. 
2015;1393:37-46
[109] Chen J, Zhao Y, Chen S, Wang J, 
Xiao X, Ma X, et al. Neuronal over-
expression of ACE2 protects brain 
from ischemia-induced damage. 
Neuropharmacology. 2014;79:550-558
[110] Tsukuda K, Mogi M, Iwanami J, 
Min LJ, Jing F, Ohshima K, et al. 
Influence of angiotensin II type 1 
receptor-associated protein on prenatal 
development and adult hypertension 
after maternal dietary protein 
restriction during pregnancy. Journal of 
the American Society of Hypertension. 
2012;6(5):324-330
[111] Campbell DJ, Alexiou T, 
Xiao HD, Fuchs S, McKinley MJ, 
Corvol P, et al. Effect of reduced 
angiotensin-converting enzyme 
gene expression and angiotensin-
converting enzyme inhibition on 
angiotensin and bradykinin peptide 
levels in mice. Hypertension. 
2004;43(4):854-859
[112] Waghe P, Sarath TS, Gupta P, 
Kandasamy K, Choudhury S, 
Kutty HS, et al. Arsenic causes aortic 
dysfunction and systemic hypertension 
in rats: Augmentation of angiotensin 
II signaling. Chemico-Biological 
Interactions. 2015;237:104-114
[113] Tufino C, Villanueva-Lopez C, 
Ibarra-Barajas M, Bracho-Valdes I, 
Bobadilla-Lugo RA. Experimental 
gestational diabetes mellitus induces 
blunted vasoconstriction and 
functional changes in the rat aorta. 
BioMed Research International. 
2014;2014:329634
[114] Nishiyama A, Seth DM, Navar LG. 
Renal interstitial fluid angiotensin 
I and angiotensin II concentrations 
during local angiotensin-converting 
enzyme inhibition. Journal of the 
American Society of Nephrology. 
2002;13(9):2207-2212
[115] Gilliam-Davis S, Payne VS, 
Kasper SO, Tommasi EN, Robbins ME, 
Diz DI. Long-term AT1 receptor 
blockade improves metabolic function 
and provides renoprotection in 
Fischer-344 rats. American Journal 
of Physiology. Heart and Circulatory 
Physiology. 2007;293(3):H1327-H1333
[116] Chappell MC, Brosnihan KB, 
Diz DI, Ferrario CM. Identification 
of angiotensin-(1-7) in rat 
brain. Evidence for differential 
processing of angiotensin peptides. 
Journal of Biological Chemistry. 
1989;264(28):16518-16523
[117] Campbell DJ, Duncan AM, 
Kladis A, Harrap SB. Angiotensin 
peptides in spontaneously hypertensive 
and normotensive Donryu rats. 
Hypertension. 1995;25(5):928-934
[118] Senanayake PS, Smeby RR, 
Martins AS, Moriguchi A, Kumagai H, 
Ganten D, et al. Adrenal, kidney, and 
heart angiotensins in female murine 
Ren-2 transfected hypertensive rats. 
Peptides. 1998;19(10):1685-1694
[119] Ocaranza MP, Lavandero S, 
Jalil JE, Moya J, Pinto M, Novoa U, et al. 
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
22
Angiotensin-(1-9) regulates cardiac 
hypertrophy in vivo and in vitro. Journal 
of Hypertension. 2010;28(5):1054-1064
[120] Senanayake PD, Moriguchi A, 
Kumagai H, Ganten D, Ferrario CM, 
Brosnihan KB. Increased expression 
of angiotensin peptides in the brain of 
transgenic hypertensive rats. Peptides. 
1994;15(5):919-926
[121] Hildebrand D, Merkel P, Eggers LF, 
Schluter H. Proteolytic processing of 
angiotensin-I in human blood plasma. 
PLoS One. 2013;8(5):e64027
[122] Schulz A, Jankowski J, Zidek W, 
Jankowski V. Absolute quantification 
of endogenous angiotensin II levels in 
human plasma using ESI-LC-MS/MS. 
Clinical Proteomics. 2014;11(1):37
[123] Lawrence AC, Evin G, Kladis A, 
Campbell DJ. An alternative strategy for 
the radioimmunoassay of angiotensin 
peptides using amino-terminal-
directed antisera: Measurement of 
eight angiotensin peptides in human 
plasma. Journal of Hypertension. 
1990;8(8):715-724
[124] Nussberger J, Brunner DB, 
Nyfeler JA, Linder L, Brunner 
HR. Measurement of immunoreactive 
angiotensin-(1-7) heptapeptide in 
human blood. Clinical Chemistry. 
2001;47(4):726-729
[125] Rubio-Ruiz ME, Del Valle-
Mondragon L, Castrejon-Tellez V, 
Carreon-Torres E, Diaz-Diaz E, 
Guarner-Lans V. Angiotensin II and 1-7 
during aging in metabolic syndrome 
rats. Expression of AT1, AT2 and Mas 
receptors in abdominal white adipose 
tissue. Peptides. 2014;57:101-108
[126] Ferrario CM, Martell N, Yunis C, 
Flack JM, Chappell MC, Brosnihan 
KB, et al. Characterization of 
angiotensin-(1-7) in the urine of normal 
and essential hypertensive subjects. 
American Journal of Hypertension. 
1998;11(2):137-146
[127] Mazzolai L, Pedrazzini T, Nicoud F, 
Gabbiani G, Brunner HR, Nussberger J. 
Increased cardiac angiotensin II levels 
induce right and left ventricular 
hypertrophy in normotensive mice. 
Hypertension. 2000;35(4):985-991
[128] Campbell DJ, Kladis A, 
Duncan AM. Nephrectomy, 
converting enzyme inhibition, and 
angiotensin peptides. Hypertension. 
1993;22(4):513-522
[129] Kuba K, Zhang L, Imai Y, Arab S, 
Chen M, Maekawa Y, et al. Impaired 
heart contractility in Apelin gene-
deficient mice associated with aging and 
pressure overload. Circulation Research. 
2007;101(4):e32-e42
[130] Shefer G, Marcus Y, Knoll E, 
Dolkart O, Foichtwanger S, Nevo N, 
et al. Angiotensin 1-7 is a negative 
modulator of aldosterone secretion 
in vitro and in vivo. Hypertension. 
2016;68(2):378-384
[131] Kanefendt F, Thuss U, Becka M, 
Boxnick S, Berse M, Schultz A, 
et al. Pharmacokinetics, safety, and 
tolerability of the novel chymase 
inhibitor BAY 1142524 in healthy male 
volunteers. Clinical Pharmacology in 
Drug Development. 2018
[132] Basu R, Poglitsch M, 
Yogasundaram H, Thomas J, Rowe 
BH, Oudit GY. Roles of angiotensin 
peptides and recombinant human 
ACE2 in heart failure. Journal of the 
American College of Cardiology. 
2017;69(7):805-819
[133] Patel VB, Lezutekong JN, Chen X, 
Oudit GY. Recombinant human ACE2 
and the angiotensin 1-7 axis as potential 
new therapies for heart failure. The 
Canadian Journal of Cardiology. 
2017;33(7):943-946
23
Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin…
DOI: http://dx.doi.org/10.5772/intechopen.87239
[134] Oudit GY, Penninger JM. 
Recombinant human angiotensin-
converting enzyme 2 as a new renin-
angiotensin system peptidase for heart 
failure therapy. Current Heart Failure 
Reports. 2011;8(3):176-183
[135] Luo D, Zhuang X, Luo C, Long M, 
Deng C, Liao X, et al. Continuous 
angiotensin-(1-7) infusion improves 
myocardial calcium transient and 
calcium transient alternans in ischemia-
induced cardiac dysfunction rats. 
Biochemical and Biophysical Research 
Communications. 2015;467(4):645-650
